eMSGait: Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device

Sponsor
Nantes University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04969848
Collaborator
(none)
44
1
9.4
4.7

Study Details

Study Description

Brief Summary

Gait alteration is frequent in MS and limitation in walking ability is a major concern in MS patients. The development of wearable device offers the opportunity to collect data during daily activity including walking.

Condition or Disease Intervention/Treatment Phase
  • Other: Wearable sensor

Detailed Description

Umanit and LMJ (Nantes university) has developed a device call eMSgait to assess walking ability in MS patients individuals (eg MS patients). This device consists in a commercialized IMU sensor (MetaMotionR Sensor, Mbientilab) worn at the right hip, a smartphone app and dedicated algorithm/mathematical model to extract raw sensor data and calculate individual gait pattern (IGP). This IGP consists of a curve, based on quaternion and representing the rotation recorded by the IMU during an average gait cycle. Pursue first pilot work assessing information from IGP on gait alteration in MS.

Study Design

Study Type:
Observational
Actual Enrollment :
44 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Uncontrolled, Single-center Study to Quantify Gait Disturbance in Patients With Multiple Sclerosis
Actual Study Start Date :
Aug 18, 2021
Actual Primary Completion Date :
May 31, 2022
Actual Study Completion Date :
May 31, 2022

Arms and Interventions

Arm Intervention/Treatment
eMSGait

Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.

Other: Wearable sensor
IMU sensor (as part of eMSGait device) worn at the hip during T25FW
Other Names:
  • MetaMotionR Sensor, Mbientilab
  • Outcome Measures

    Primary Outcome Measures

    1. Correlation with disability [One time point per patient (inclusion)]

      Correlation of gait measures (mean amplitude of walking cycles (m), mean duration of walking cycles (s), Stance swing phase ratio) obtained during a walk of 25 feet with Expanded Disability Status Scale (EDSS). EDSS is an ordinal scale measuring disability and ranging from 0 (normal examination) to 10 (death due to MS) in a 0,5-point increments from score 1.

    Secondary Outcome Measures

    1. Correlation with neurological function [One time point per patient (inclusion)]

      Pyramidal, cerebellar and sensory functions are assessed with Kurtzke functional system scores which are based on neurological examination. Scores of the Pyramidal and sensory systems range from 0 (normal) to 6 . Cerebellar system scores range from 0 (normal) to 6. Cerebellar system scores range from 0 (normal) to 5

    2. Correlation with gait speed [One time point per patient (inclusion)]

      Timed 25-Foot Walk (T25FW). T25FW measures the time needed to complete a 25-foot walk. Two trials are averaged

    3. Correlation with lateralization [One time point per patient (inclusion)]

      Lower limb lateralization (right vs left)

    4. Correlation with disability location [One time point per patient (inclusion)]

      Upper, lower limb, trunk MS symptoms location

    5. Correlation with MS symptoms severity [One time point per patient (inclusion)]

      MS symptoms severity quote as none, mild moderate severe

    6. Reliability of sensor measures [At the inclusion]

      Gait parameters record during a 25-foot walk repeated twice at 5 min apart.

    7. Developement of dedicated algorithm to improve signal processing from IMU. [Day 1]

      Number of detected gait cycles during a foot walk.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 64 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18 - 64 years

    • Diagnosis of MS based on McDonald criteria (including Relapsing-remitting and progressive MS)

    • No relapse within the last 5 weeks before recruitment

    • Able to walk with or without assistance/help/aid (one or 2 canes)

    • EDSS [0-6]

    Exclusion Criteria:
    • Women who are pregnant

    • Patient having expressed their opposition

    • Patient under guardianship or security measure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nantes University Hospital Nantes Loire-Atlantique France 44093

    Sponsors and Collaborators

    • Nantes University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nantes University Hospital
    ClinicalTrials.gov Identifier:
    NCT04969848
    Other Study ID Numbers:
    • RC21_0070
    First Posted:
    Jul 21, 2021
    Last Update Posted:
    Jun 3, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nantes University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 3, 2022